Overview

Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients

Status:
Recruiting

Trial end date:
2022-04-28

Target enrollment:

Participant gender:

Summary

This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Bromides
Formoterol Fumarate